Journal article icon

Journal article

Sodium valproate, a histone deacetylase inhibitor, is associated with reduced stroke risk after previous ischemic stroke or transient ischemic attack

Abstract:

A variant in the histone deacetylase 9 (HDAC9) gene is associated with large artery stroke. Therefore, inhibiting HDAC9 might offer a novel secondary preventative treatment for ischemic stroke. The antiepileptic drug sodium valproate (SVA) is a nonspecific inhibitor of HDAC9. We tested whether SVA therapy given after ischemic stroke was associated with reduced recurrent stroke rate.Data were pooled from 3 prospective studies recruiting patients with previous stroke or transient ischemic attac...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.1161/strokeaha.117.016674

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Clinical Neurosciences
Role:
Author
Expand authors...
Publisher:
American Heart Association Publisher's website
Journal:
Stroke Journal website
Volume:
49
Issue:
1
Pages:
54-61
Publication date:
2017-12-15
Acceptance date:
2017-10-02
DOI:
EISSN:
1524-4628
ISSN:
0039-2499
Pubs id:
pubs:813044
URN:
uri:8f9032d7-c613-49f9-b8b4-b6379ae2ffa1
UUID:
uuid:8f9032d7-c613-49f9-b8b4-b6379ae2ffa1
Local pid:
pubs:813044
Paper number:
1

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP